Browse ATP2A3

Summary
SymbolATP2A3
NameATPase, Ca++ transporting, ubiquitous
Aliases SERCA3; sarcoplasmic/endoplasmic reticulum calcium ATPase 3; calcium pump 3; ATPase, Ca(2+)-transporting, ub ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus membrane Multi-pass membrane protein Endoplasmic reticulum membrane Multi-pass membrane protein Sarcoplasmic reticulum membrane Multi-pass membrane protein
Domain PF00689 Cation transporting ATPase
PF00690 Cation transporter/ATPase
Function

This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of calcium. Transports calcium ions from the cytosol into the sarcoplasmic/endoplasmic reticulum lumen. Contributes to calcium sequestration involved in muscular excitation/contraction.

> Gene Ontology
 
Biological Process GO:0003013 circulatory system process
GO:0003015 heart process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0035637 multicellular organismal signaling
GO:0044057 regulation of system process
GO:0055074 calcium ion homeostasis
GO:0060047 heart contraction
GO:0061337 cardiac conduction
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:1903522 regulation of blood circulation
GO:1903779 regulation of cardiac conduction
Molecular Function GO:0005388 calcium-transporting ATPase activity
GO:0015085 calcium ion transmembrane transporter activity
GO:0015399 primary active transmembrane transporter activity
GO:0015405 P-P-bond-hydrolysis-driven transmembrane transporter activity
GO:0015662 ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism
GO:0016820 hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances
GO:0016887 ATPase activity
GO:0019829 cation-transporting ATPase activity
GO:0022804 active transmembrane transporter activity
GO:0022853 active ion transmembrane transporter activity
GO:0042623 ATPase activity, coupled
GO:0042625 ATPase coupled ion transmembrane transporter activity
GO:0042626 ATPase activity, coupled to transmembrane movement of substances
GO:0043492 ATPase activity, coupled to movement of substances
GO:0046873 metal ion transmembrane transporter activity
GO:0072509 divalent inorganic cation transmembrane transporter activity
Cellular Component GO:0005635 nuclear envelope
GO:0016528 sarcoplasm
GO:0016529 sarcoplasmic reticulum
GO:0031094 platelet dense tubular network
GO:0031095 platelet dense tubular network membrane
GO:0031965 nuclear membrane
GO:0033017 sarcoplasmic reticulum membrane
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04972 Pancreatic secretion
Reactome R-HSA-5576891: Cardiac conduction
R-HSA-109582: Hemostasis
R-HSA-983712: Ion channel transport
R-HSA-5578775: Ion homeostasis
R-HSA-936837: Ion transport by P-type ATPases
R-HSA-397014: Muscle contraction
R-HSA-418360: Platelet calcium homeostasis
R-HSA-418346: Platelet homeostasis
R-HSA-1912422: Pre-NOTCH Expression and Processing
R-HSA-1912420: Pre-NOTCH Processing in Golgi
R-HSA-418359: Reduction of cytosolic Ca++ levels
R-HSA-162582: Signal Transduction
R-HSA-157118: Signaling by NOTCH
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolATP2A3
NameATPase, Ca++ transporting, ubiquitous
Aliases SERCA3; sarcoplasmic/endoplasmic reticulum calcium ATPase 3; calcium pump 3; ATPase, Ca(2+)-transporting, ub ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ATP2A3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ATP2A3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22851172Breast CarcinomaInhibit immunityHere, we show that human CD4(+) T cells in the presence of tumor conditions manifested an up-regulation of SERCA3 expression that resulted in development of endoplasmic reticulum stress leading to CD4(+) T cell apoptosis. Gene manipulation and pharmacological approaches further established that an increase in SERCA expression also resulted in subsequent inhibition of PKCα and -θ and retention of NFκB in the cytosol; however, down-modulation of SERCA3 expression by a dihydropyrimidone derivative, ethyl-4-(3-nitro)-phenyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5 carboxylate (nifetepimine), protected the CD4(+) T cells from tumor-induced apoptosis.
Summary
SymbolATP2A3
NameATPase, Ca++ transporting, ubiquitous
Aliases SERCA3; sarcoplasmic/endoplasmic reticulum calcium ATPase 3; calcium pump 3; ATPase, Ca(2+)-transporting, ub ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ATP2A3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolATP2A3
NameATPase, Ca++ transporting, ubiquitous
Aliases SERCA3; sarcoplasmic/endoplasmic reticulum calcium ATPase 3; calcium pump 3; ATPase, Ca(2+)-transporting, ub ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ATP2A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2030.721
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.290.856
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5670.656
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5430.181
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4230.851
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6920.803
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9190.101
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.5980.201
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1530.914
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1230.347
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2720.463
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0770.643
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ATP2A3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1032033.3-13.31
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolATP2A3
NameATPase, Ca++ transporting, ubiquitous
Aliases SERCA3; sarcoplasmic/endoplasmic reticulum calcium ATPase 3; calcium pump 3; ATPase, Ca(2+)-transporting, ub ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ATP2A3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolATP2A3
NameATPase, Ca++ transporting, ubiquitous
Aliases SERCA3; sarcoplasmic/endoplasmic reticulum calcium ATPase 3; calcium pump 3; ATPase, Ca(2+)-transporting, ub ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ATP2A3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ATP2A3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolATP2A3
NameATPase, Ca++ transporting, ubiquitous
Aliases SERCA3; sarcoplasmic/endoplasmic reticulum calcium ATPase 3; calcium pump 3; ATPase, Ca(2+)-transporting, ub ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ATP2A3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolATP2A3
NameATPase, Ca++ transporting, ubiquitous
Aliases SERCA3; sarcoplasmic/endoplasmic reticulum calcium ATPase 3; calcium pump 3; ATPase, Ca(2+)-transporting, ub ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ATP2A3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolATP2A3
NameATPase, Ca++ transporting, ubiquitous
Aliases SERCA3; sarcoplasmic/endoplasmic reticulum calcium ATPase 3; calcium pump 3; ATPase, Ca(2+)-transporting, ub ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ATP2A3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolATP2A3
NameATPase, Ca++ transporting, ubiquitous
Aliases SERCA3; sarcoplasmic/endoplasmic reticulum calcium ATPase 3; calcium pump 3; ATPase, Ca(2+)-transporting, ub ......
Chromosomal Location17p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ATP2A3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.